Swisher E M, Shawler D L, Collins H A, Bustria A, Hart S, Bloomfield C, Miller R A, Royston I
UCSD Cancer Center.
Blood. 1991 May 1;77(9):1977-82.
The expression of shared idiotypes (Slds) has been studied on malignant CD5+B cells from patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) using a panel of 37 murine monoclonal antibodies previously demonstrated to be reactive with Slds derived from follicular B-cell lymphomas. Thirteen anti-Slds identified tumor cells from 31 of 105 (30%) CLL patients and 4 of 6 SLL patients. In comparison, the same panel of anti-Slds is reactive with 33% of follicular and diffuse B-cell lymphomas. Ten of these anti-Slds reacted with CLL cases at similar frequencies to that of the B-cell lymphomas. Two anti-Slds, which are known to react with autoantibodies, were significantly more prevalent in CLL than in B-cell lymphomas. These data confirm the presence of Slds in CLL and provide further evidence of an association between CLL and autoimmunity. The identification of a panel of antibodies reactive with a significant number of CLL and SLL patients will facilitate the application of anti-idiotype antibody therapy in these diseases.
利用一组先前已证明可与源自滤泡性B细胞淋巴瘤的共享独特型（Slds）发生反应的37种鼠单克隆抗体，对慢性淋巴细胞白血病（CLL）和小淋巴细胞淋巴瘤（SLL）患者的恶性CD5 + B细胞上的Slds表达进行了研究。13种抗Slds抗体鉴定出105例CLL患者中的31例（30%）以及6例SLL患者中的4例的肿瘤细胞。相比之下，同一组抗Slds抗体可与33%的滤泡性和弥漫性B细胞淋巴瘤发生反应。其中10种抗Slds抗体与CLL病例的反应频率与B细胞淋巴瘤相似。两种已知可与自身抗体发生反应的抗Slds抗体在CLL中比在B细胞淋巴瘤中更为普遍。这些数据证实了CLL中存在Slds，并进一步证明了CLL与自身免疫之间的关联。鉴定出一组可与大量CLL和SLL患者发生反应的抗体将有助于在这些疾病中应用抗独特型抗体疗法。
